Inovio targets October 30 PDUFA date for INO-3107 approval while extending cash runway into Q4 2026 (NASDAQ:INO)

Core Insights - Inovio Pharmaceuticals is targeting an October 30 PDUFA date for the approval of INO-3107, which is positioned as a potential treatment for adults with recurrent respiratory papillomatosis (RRP) [2] - The company has successfully extended its cash runway into the fourth quarter of 2026, indicating financial stability and operational continuity [2] Management View - CEO Jacqueline Shea emphasized the significance of the upcoming BLA for INO-3107, highlighting the excitement surrounding the potential treatment for RRP [2]